article thumbnail

India’s Growing Importance in Generic Drug API Manufacturing

Drug Patent Watch

India has long been recognized as a significant player in the global pharmaceutical industry, particularly in the production of generic drugs. This article delves into India’s growing importance in generic drug API manufacturing, highlighting the key factors contributing to its success and the challenges it faces. Califf, M.D.,

article thumbnail

Pharmacognosy and Drug Patents: Unveiling Nature’s Medicinal Treasures

Drug Patent Watch

This intersection is where pharmacognosy meets drug patents, creating a unique landscape that shapes the future of medicine. But what exactly is pharmacognosy, and how does it relate to the complex world of drug patents? This approach has led to the discovery of numerous potential drug candidates.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Drug Channels News Roundup, July 2025: 340B vs. Patients, Humira Whiplash, Accumulator Fallout, and Pharmacy Struggles

Drug Channels

Let’s cut through the steamy summer haze with a refreshing breeze of industry insights from Drug Channels—perfect for pondering while you float in your favorite pool: 340B Discounts Still Not Reaching Needy Patients Why do patients switch from biosimilars back to Humira? Copay accumulator programs strike again! All rights reserved.

article thumbnail

From siloed data to breakthroughs: multimodal AI in drug discovery

Drug Target Review

Drug development is plagued by complex challenges, but multimodal AI is unlocking new opportunities. By integrating diverse data sources – from genomics to clinical insights – this approach is accelerating drug discovery, improving patient stratification and boosting success rates.

article thumbnail

The Top 15 Specialty Pharmacies of 2024: How PBMs, Health Systems, and Independents Are Shaping the Market (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: What’s Next for Retail Pharmacy: Data, Debate, and Disruption. Drug Channels Institute’s (DCI’s) latest analysis reveals that PBM-affiliated specialty pharmacies continue to dominate the dispensing of specialty drugs.

article thumbnail

New cell therapy model accelerates cancer treatment development

Drug Target Review

Unlike traditional drug manufacturing, where the supply chain is linear, autologous cell therapies involve a more complex, circular process. In this model, once a product is produced and delivered to the clinical pharmacy, the clinical team takes over the trial with little to no interaction with the manufacturing team.

article thumbnail

How the IRA’s Part B Coinsurance Inflation Adjustments Can Raise Seniors’ Drug Costs

Drug Channels

The Inflation Reduction Act (IRA) is triggering increases in Medicare beneficiaries spending on their Part B drugs. We find that a growing number of Part B drugs now have inflation-adjusted coinsurance rates that are rising, not falling. Retail Pharmacy Update 2025: Data, Debate, and Disruption. Fein and Antonio Ciaccia.